Last reviewed · How we verify
Placebo Nux vomica
Placebo Nux vomica is a Small molecule drug developed by Shaare Zedek Medical Center. It is currently in Phase 3 development for Control arm in phase 3 clinical trial (specific indication unknown).
This is a placebo formulation with no active pharmacological mechanism.
This is a placebo formulation with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trial (specific indication unknown).
At a glance
| Generic name | Placebo Nux vomica |
|---|---|
| Sponsor | Shaare Zedek Medical Center |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo Nux vomica is a control preparation used in clinical trials, containing inert or highly diluted Nux vomica (strychnine tree extract) with no measurable active ingredient. It serves as a comparator arm in phase 3 studies to assess efficacy of investigational treatments against baseline/control conditions.
Approved indications
- Control arm in phase 3 clinical trial (specific indication unknown)
Common side effects
Key clinical trials
- Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery (PHASE4)
- Response to Supplement and Placebo in GERD (NA)
- Homeopathic Treatment of Premenstrual Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Nux vomica CI brief — competitive landscape report
- Placebo Nux vomica updates RSS · CI watch RSS
- Shaare Zedek Medical Center portfolio CI